Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.45 USD | +2.91% |
|
+9.80% | +42.93% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+42.93% | 285M | C+ | ||
+17.72% | 44.87B | - | B- | |
-10.33% | 37.8B | B | ||
+40.49% | 37.61B | A | ||
+29.36% | 31.32B | B | ||
-8.44% | 27.4B | C | ||
+12.45% | 26.32B | B- | ||
+44.19% | 14.07B | B+ | ||
+31.93% | 12.5B | C+ | ||
-7.67% | 11.23B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ENTA Stock
- Ratings Enanta Pharmaceuticals, Inc.